Hot Investor Mandate: USA-Based VC Invests Up to $25M in Therapeutics & Platform Technologies From Pre-Clinical to Phase 3 in All Indication Areas

9 Jul

A venture capital firm founded in the USA closed its first fund in 2017 and is actively seeking new investment opportunities. The fund will make 15-20 investments in total with no set number of investments per year. The firm will be actively involved in their portfolio companies and will invest up to $25 million over the life of each portfolio company. Initial check sizes will depend on the company’s stage of development and their needs prior to investment. The firm will invest in North American or European companies.

The firm is focused solely on therapeutics and therapeutic platforms. The fund will invest at any stage of development from preclinical / discovery stage through Phase 3 clinical, and will invest in all therapeutic areas.

The firm can work with companies at all stages of their evolution. The firm’s team has the capability and experience to build companies from the ground up, however generally gets involved with at least the beginnings of a management team in place. The firm can both lead and co-invest along syndicates and will generally seek board representation in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm in USA Seeks Early-Stage Investment Opportunities in Devices, Diagnostics, Digital Health, Life Science Research Tools

9 Jul

A venture capital company based in USA manages just under $70 million in assets across 2 funds and makes equity investments into companies ranging from a few hundred thousand dollars to $2million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States  and plans to make 4 new investments over the next 6-9 months.

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. For Healthcare IT investments the firm is most interested in machine learning and artificial intelligence (AI) applications and is generally not interested in Telehealth and EMR solutions. The firm is open to all sub-sectors and indications in the Medical technology space except for those targeting diseases and disorders of the spine. The firm will invest in both seed and later stage companies.

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play and active role in the management. The firm is willing to invest in both public and privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Partnered with Strategic Partner Invests Up to $30M in Medical Devices, Also Open to Therapeutics with Established PoC

9 Jul

A private investment firm based in USA makes co-investments into early stage life science companies.  The firm prefers to invest in Series A-B rounds, and does not make seed investments.  The firm makes investments of up to $300,000 out of the firm’s own capital, and is also working with an international partner that makes investments of up to $30 million in medical devices. The firm invests in startups US-wide.

The firm invests broadly in the life sciences and will consider opportunities in therapeutics, devices, diagnostics, healthcare IT and life science tools. The firm’s partner org is focused on late stage opportunities in the electronic medical device sector and will invest up to $30 million in these opportunities, with an interest in opportunities in which this org can act as a manufacturing partner.  In other sectors, the firm makes early stage investments in companies that have established proof of concept, and interests include  orphan drugs, the microbiome, healthcare data science, tools and some devices.

The firm prefers to invest in companies that have already received a significant round of funding in the past.  For data and healthcare IT companies, initial revenues are preferred.  The firm focuses on opportunities that will provide a short path to exit. The firm takes an active role with portfolio companies, particularly in making strategic and market connections with partners in Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Increase Your Exposure at Digital RESI September

2 Jul

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claire

We are excited to announce the launch of two opportunities to increase your company’s exposure at the Digital Redefining Early Stage Investments (RESI) Conference in September – The Innovation Challenge and Featured Company Pitch Sessions.

Showcase Your Technology at the Innovation Challenge

This marks our third time organizing the Innovation Challenge in a digital format. The Innovation Challenge is always a great opportunity to increase your exposure and showcase your technology. 30 finalists will be selected from a pool of over 100 applicants, and all companies will have their own dedicated page to upload their virtual poster, video, and other supplementary materials. RESI attendees will be able to vote for up to 5 companies that they find the most innovative.

If you are interested in increasing your visibility to 400+ investors, please apply! The deadline is Wednesday, August 12th.

Pitch Your Company to a Panel of Investors

The Featured Company Pitch Session is a great opportunity to gain exposure for your company and get valuable feedback from a panel of investors. For an added fee, companies get a dedicated page featuring their pitch, followed by a virtual Q&A session with a panel of investors and a live audience. Applications are accepted on a rolling basis, so make sure to submit your application as soon as possible!

2nd Call for Panelists for LSN’s Inaugural 4D Meets AI Digital Partnering Conference

2 Jul

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

4D Meets AI is Life Science Nation (LSN)’s newest digital partnering conference advancing Drugs, Diagnostics, Devices, and Digital Health (4 Ds) through the power of Artificial Intelligence (AI). We are still accepting applications for new panelists, and if you are an early-stage company developing new tech to advance healthcare or an investor with industry insight, joining a panel gives you increased exposure to share your story with CEOs and strategic partners.

Participation in a 50-minute pre-recorded panel will provide waived registration to the 2-day digital event, including access to all panels, as well as our unique partnering platform. To read about each panel at 4D Meets AI and apply to be featured as a panelist or moderator, visit the 4D Meets AI panel page.

Business as (Un)usual During the Covid-19 Pandemic

2 Jul

Andy Merken
Partner at Burns & Levinson and Co-Chair of the Life Sciences Group

Gregory Mannix
Chief Conference Officer, VP International Business Development, LSN

After the major disruptions of the last few months, everyone has readjusted to a new normal. I recently spoke with Andy Merken, Partner at Burns & Levinson and Co-Chair of the Life Sciences Group, to learn his perspective of how things have changed, and how the industry has evolved.

GREG MANNIX (GM): These are certainly crazy times. How has the Covid-19 pandemic affected your work at Burns & Levinson?

ANDY MERKEN (AM): Crazy is an understatement. March was a time of uncertainty, with everyone in the business world – clients, their business partners, investors, and M&A  professionals – trying to get their heads around what was happening and how it would impact their businesses and the broader life sciences industry. From a few rumblings in late February/early March to almost a full-blown panic starting in mid-March, client work continued forward unabated but with a growing sense of uneasiness. The first few weeks of April were consumed with helping clients navigate all of the questions – and the almost-daily changing guidance – with respect to PPP Loans, particularly for venture-backed companies. A number of deals were put on hold in April and early May, but the good news is that most of them have now returned, though some with slightly less favorable deal terms, particularly for medical device deals. Deal terms for biotech, pharma, healthcare IT and healthcare services all seem to be holding steady. What we are finding now in early July is that workflow is almost back to normal – both day-to-day matters as well as patent filings, financings (both seed stage and venture stage) and M&A. There is a growing sense of optimism that the worst is over – not with respect to the pandemic itself but as to the long-term business impact that it will have on our clients.

GM: Do you think any of these new ways of communicating, like videoconference calls, are here to stay after the pandemic is over?

AM: Absolutely. I have been pleasantly surprised at how seamless the transition has been from the physical world to the virtual world. After a week or two of people saying, “Zoom? Why would I want people to see me working at my dining room table?”, everyone has jumped on the videoconference and remote working bandwagon in earnest. We are  finding that productivity has not been harmed, and in fact, has actually improved given the loss – in a good way – of commuting time for most people. That being said, there are still business advantages to being able to meet people in person (especially new contacts), to walk down the hallway to chat with a co-worker, and generally to collaborate. For these reasons, I believe that in-person workplaces will return in full force, but with  videoconference calls  remaining much more a part of our daily work lives moving forward.

GM: Burns & Levinson is a sponsor of RESI, and you have been to a number of on-site RESI conferences across the country. Since we had to make the pivot to a digital RESI, what was your impression of the new format? Was it a productive way to interact with people?

AM: The new format exceeded my expectations. The videoconference technology was seamless. Just about everyone that I spoke to, as part of RESI, had the same comments. And, for those doing the 1-to-1 partnering meetings, they benefited from the conference being held for 3 days instead of 1, the ability to meet people from other parts of the country and all over the world who otherwise would not have been able to travel in, and the ability to meet people across multiple time zones. Those that I spoke with were thrilled with the scheduling flexibility and the ability to meet more people than at an in-person event. Nevertheless, people would still like the opportunity to meet live, especially when they are already traveling in for JPM, BIO, Boston Biotech Week and other conferences that RESI is scheduled around. It may be that a hybrid approach is what ultimately makes the most sense – in-person, but with a digital component, as well.

GM: Burns & Levinson will be a Gold Sponsor at both Digital RESI and the new 4D Meets AI conference coming up in September. Is the firm planning any specific educational content for the early-stage companies who are participating?

AM: Yes. We are really excited about being involved with both conferences. We are still in the early planning stages for panels and presentations, but areas that we hope to be able to cover for early-stage companies include overviews of, and issues relating to, seed stage and venture capital financings, patent prosecution, in-licensing and out-licensing,and the FDA process and regulatory scheme.

GM: We all miss the in-person seminars and networking events of the past, and it is hard to guess when things like that will resume. Are you planning any web-based informative sessions or webinars over the next few months to partially fill that gap?

AM: We certainly are. Just last week we hosted a virtual panel entitled “Life Sciences M&A and VC Financing Update: Dealmaking During the Pandemic”. Panelists were Randy Scott of HealthQuest Capital, Tom Miller of GreyBird Ventures, and Ben Conway of Consilium Partners – 2 Venture Capital investors and 1 Investment Banker. Tom and Randy, by the way, are active participants in RESI. We had over 140 attendees register for what was a very informative panel discussion and Q&A, followed by breakout room networking, about the current state of life sciences VC financing and M&A, including changes to valuations, deal terms and timelines caused by COVID-19, as well as predictions for the short- and long-term future. This event took the place of a summer in-person event that we typically run. We have gotten great feedback from attendees and are planning to offer quarterly panels. We are considering a “CEO Forum” for the fall, where life science CEOs can discuss their companies and what they are seeing in the industry. This idea came from talking with one of the attendees, so we are reaching out to our network to source ideas for additional panels – please contact me with ideas!

Hot Investor Mandate: USA Healthcare VC Firm Invests Up to $25M in Therapeutics Companies in Oncology & Platform Technologies Across the Globe

2 Jul

A healthcare investment firm with offices in USA  actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. The firm makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.